Proposed strategies for managing clopidogrel hypersensitivity include treatment with an alternative P2Y12 inhibitor, cilostazol, or warfarin.
What are the recommended alternative antiplatelet agents for patients with clopidogrel hypersensitivity?
For patients with clopidogrel hypersensitivity, alternative P2Y12 inhibitors, cilostazol, or warfarin are recommended to maintain secondary prevention of vascular events.
Clopidogrel is a widely used agent for secondary prevention of vascular events and is a cornerstone of dual antiplatelet therapy in patients with acute coronary syndrome (ACS) post coronary stent implantation. Hypersensitivity reactions to clopidogrel are well documented and may range from localized to systemic in presentation. This can lead to discontinuation of therapy, thus increasing the risk of vascular events. The authors have developed recommendations for potential alternative agents for the management of clopidogrel hypersensitivity reactions. Proposed strategies include treatment with an alternative P2Y12 inhibitor, cilostazol or warfarin.
Ather et al. (Wed,) conducted a review in Clopidogrel hypersensitivity. Alternative antiplatelet agents (alternative P2Y12 inhibitor, cilostazol, or warfarin) was evaluated. Proposed strategies for managing clopidogrel hypersensitivity include treatment with an alternative P2Y12 inhibitor, cilostazol, or warfarin.